Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AEMD
stocks logo

AEMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
--
--
-2.420
-76.73%
--
--
-1.920
-94.81%
--
--
-1.400
-83.53%
Estimates Revision
The market is revising No Change the revenue expectations for Aethlon Medical, Inc. (AEMD) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -44.18%.
EPS Estimates for FY2026
Revise Downward
down Image
-54.2%
In Past 3 Month
Stock Price
Go Down
down Image
-44.18%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Aethlon Medical Inc (AEMD.O) is -0.56, compared to its 5-year average forward P/E of -2.25. For a more detailed relative valuation and DCF analysis to assess Aethlon Medical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.25
Current PE
-0.56
Overvalued PE
0.43
Undervalued PE
-4.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.24
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.53
Undervalued EV/EBITDA
-1.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
13.76
Current PS
0.00
Overvalued PS
34.87
Undervalued PS
-7.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

AEMD News & Events

Events Timeline

(ET)
2025-12-02
08:10:00
Aethlon Medical to Publish Long COVID Study on November 20, 2025
select
2025-11-12 (ET)
2025-11-12
16:20:26
Aethlon Medical announces Q2 earnings per share of $3.74, compared to a loss of $16.11 in the same period last year.
select
2025-09-04 (ET)
2025-09-04
09:21:13
Aethlon Medical reveals pricing for $4.5M common stock and warrant sale
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
12-03Benzinga
American Eagle Shares Rise 15%; Check Out 20 Stocks Making Moves in Premarket Trading

  • American Eagle Outfitters Performance: American Eagle Outfitters Inc. reported third-quarter revenue of $1.36 billion and adjusted earnings of 53 cents per share, both exceeding analyst expectations, leading to a 14.8% increase in share price during pre-market trading.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Powell Max Ltd (up 70%), Creative Media & Community Trust Corp (up 53.3%), and SMX (up 27.3%).

  • Significant Losers: Lulu’s Fashion Lounge Holdings Inc. experienced a dramatic drop of 58.3%, while ScanTech AI Systems Inc. fell 35.8% after receiving a delisting determination from Nasdaq.

  • Market Reactions: The overall market showed mixed reactions with various companies reporting earnings and guidance updates, impacting their stock prices significantly in pre-market trading.

[object Object]
Preview
9.0
12-02PRnewswire
Aethlon Medical Publishes Long COVID Study Findings
  • Research Advancement: Aethlon Medical's preclinical study published on November 20, 2025, indicates that elevated extracellular vesicles in Long COVID plasma may provide a therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin, suggesting potential breakthroughs in Long COVID treatment.
  • Clinical Collaboration: The study, conducted in partnership with the UCSF Long COVID clinic, analyzed plasma samples from Long COVID patients and recovered controls, revealing significantly higher levels of extracellular vesicles in Long COVID patients, highlighting the device's potential application in treating post-COVID symptoms.
  • Technological Innovation: The Hemopurifier® device effectively removes harmful extracellular vesicles through plasma separation and GNA affinity resin, previously demonstrated in severe acute COVID-19 patients, indicating its potential efficacy in Long COVID patients and expanding its clinical application scope.
  • Market Potential: With Long COVID affecting 44 to 48 million people in the U.S. and an estimated economic burden of $2 billion, Aethlon's research findings could introduce new treatment options in this area, enhancing the company's competitiveness in the medical device market.
[object Object]
Preview
9.0
12-02Newsfilter
Aethlon Medical Publishes Long COVID Study Results
  • Research Advancement: Aethlon Medical's preclinical study published on November 20, 2025, reveals significantly increased extracellular vesicles in Long COVID plasma, providing a potential therapeutic target for Galanthus nivalis agglutinin affinity resin, paving the way for new treatment developments.
  • Economic Impact: With Long COVID affecting 44 to 48 million people in the U.S. and a projected economic burden of $2 billion, Aethlon's research offers new hope for addressing this major public health issue, potentially attracting more research funding.
  • Technological Innovation: The Hemopurifier® device effectively removes harmful extracellular vesicles through plasma separation and specific affinity resin, demonstrating potential in Long COVID treatment and possibly altering existing therapeutic strategies.
  • Clinical Collaboration: Aethlon's collaboration with the UCSF Long COVID clinic to analyze patient plasma samples indicates the device's effectiveness in removing microRNAs associated with inflammation, potentially supporting future clinical trials.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aethlon Medical Inc (AEMD) stock price today?

The current price of AEMD is 4.03 USD — it has increased 8.92 % in the last trading day.

arrow icon

What is Aethlon Medical Inc (AEMD)'s business?

Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

arrow icon

What is the price predicton of AEMD Stock?

Wall Street analysts forecast AEMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AEMD is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aethlon Medical Inc (AEMD)'s revenue for the last quarter?

Aethlon Medical Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Aethlon Medical Inc (AEMD)'s earnings per share (EPS) for the last quarter?

Aethlon Medical Inc. EPS for the last quarter amounts to -37.41 USD, increased 132.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aethlon Medical Inc (AEMD)'s fundamentals?

The market is revising No Change the revenue expectations for Aethlon Medical, Inc. (AEMD) for FY2026, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -44.18%.
arrow icon

How many employees does Aethlon Medical Inc (AEMD). have?

Aethlon Medical Inc (AEMD) has 9 emplpoyees as of December 05 2025.

arrow icon

What is Aethlon Medical Inc (AEMD) market cap?

Today AEMD has the market capitalization of 3.01M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free